GSK said that its urinary tract infections treatment gepotidacin has been accepted for priority review by the U.S.'s Food and Drug Administration.

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...

The aerospace company said late Friday it will cut 10% of its workforce, or roughly 17,000 jobs, and warned of deeper losses. Shares slipped ...

Nigeria’s healthcare sector, though growing steadily, remains significantly inadequate in the broader economy, according to financial analyst and CEO of ...

The Alabama-based sand and gravel producer declared its quarterly dividend late Friday. Shares fell more than 6% in off-hours trading. ↘️ Boeing (BA): The aerospace company ...

These FTSE shares don’t have the highest yields. But Edward Sheldon believes they could deliver attractive returns in the ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...

SG Americas Securities LLC increased its position in GSK plc (NYSE:GSK – Free Report) by 167.3% in the third quarter, ...

The artificial intelligence (AI) market has created some monster growth stocks already, but companies involved in enabling this technological revolution are still seeing growing opportunities. Here ...

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...